

Final Outcomes Summary
Data from 8/28/20 -8/28/21
Genentech G-86076

Longitudinal Management of Chronic Rhinosinusitis with Nasal Polyps



Breathing Science is Life.

Program Overview

The goal of this online educational activity is to improve clinicians' knowledge and competence within the educational gaps of diagnosis, longitudinal management and treatment of chronic rhinosinusitis with nasal polyps (CRSwNP).


This chapterized online activity is designed to optimize learner retention through microlearning strategies; four chapters, 15 minutes in length, offer learners privileged insights into the experiences of leading experts in easily accessible and organized segments. Each chapter highlights the unique experience and therapeutic knowledge of the expert faculty presenters, allowing the learner to consume multiple chapters at their convenience from one landing page.

Learning Objectives


- 1. Explain the characteristics of nasal polyps and key concepts relative to the pathophysiology and immunology of CRSwNP.
- 2. Describe best practices for diagnosis and comprehensive assessment of CRSwNP.
- 3. Analyze strategies for longitudinal management of CRSwNP.
- 4. Select treatments based on individual patient factors and recent clinical studies regarding current and emerging treatment options for CRSwNP.



Faculty Members



Flavia Cecilia Lega Hoyte, MD (Activity Co-chair)
Associate Professor of Medicine
Division of Allergy/Immunology
Fellowship Training Program Director
National Jewish Health and University of Colorado
Denver, Colorado




Anne Getz, MD (Activity Co-chair)
Associate Professor of Otolaryngology
Head and Neck Surgery
National Jewish Health and University of Colorado
Denver, Colorado




Management of Chronic Rhinosinusitis with Nasal Polyps

Program Features



Animation clips

Clinical Reference Aid



Learner Definitions – Online Activity

Launched on Medscape: August 28, 2020

https://www.medscape.org/viewarticle/935692



Longitudinal Management of Chronic Rhinosinusitis With Nasal Polyps

Authors: Flavia Cecilia Lega Hoyte, MD (Activity Co-chair): Anne Getz, MD (Activity Co-chair): Faculty and Disclosures

CME Released: 8/28/2020 Valid for credit through: 8/28/2021

Please answer the questions that appear during the activity: Choose an answer, scroll down, and click "Submit." See responses, scroll down, and click "Continue.







CME Information

Download Slides

Activity Transcript

PDF Downloads Resource








Platform	Learner Definition	Learner Guarantees	Learner Actuals
Medscape	Progressed past front-matter (unique)	3,000	5,977
	Completer Definition	Completer Guarantees	Completer Actuals
Medscape	Completed post-test	400	2,462
	Certificate Earner Definition	Certificate Guarantee	Certificate Actuals
Medscape	Completed post-test and evaluation	N/A	1,530

Surpassed learner guarantees by 2,977 and completers by 2,062!


Educational Impact Summary

Participation by Completers




*Medscape provides designation breakdown for completers only

Overall Knowledge Gain



80% relative gain in knowledge37% absolute gain in knowledge

Knowledge gains by objective



Top Intended Practice Changes

89% of evaluation respondents (N=2070) reported intended changes to practice:

- Consider biologic therapy
- ✓ Apply guidelines for improved longitudinal management of CRSwNP
- ✓ Better educate patients about chronic rhinosinusitis
- ✓ Improve diagnostic approach

92%

N=2070

Evaluation respondents intend to use the resources provided in practice

"The organization of this activity was superb. Please make more activities similarly."

"Excellent presentation; others need to learn from this."

Online learners

Educational Impact Summary

Evaluation Respondents

2,070

Evaluation respondents

Who see

14,436

CRSwNP patients Weekly

Which translates to **750,672**potential patient visits annually

Educational Impact

Knowledge regarding longitudinal management strategies increased by **464%** from pre to post-activity [N=2462]


95% of evaluation respondents indicated that the information presented reinforced and/or improved their current skills. [N=2070]

96% of evaluation respondents indicated that the activity contributed valuable information that will assist in improving quality of care for patients. [N=2070]

89% of evaluation respondents indicated they intend to make changes to their practice based on the education, in the areas of improving patient screening, appropriate management and referral, use of biologic therapies, and patient education. [N=2070]

60% of evaluation respondents indicated the education addressed strategies for overcoming barriers to optimal patient care, including access to treatment or clinical trials, cost of therapy, lack of training, patient adherence, patient knowledge, and staffing. [N=621]

Level 1 Outcomes: Participation (Degree) - Completers




93% of completers

were physicians and advanced practice providers

Degree	Total
MD/DO	1774
PA	308
APN	199
PharmD	23
Other	158
TOTAL	2462



Level 1 Outcomes: Participation (Specialty) - Completers




1-2% for each of these specialties:

Pediatrics, Emergency, Dermatology, Anesthesiology, Cardiology, Radiology, Critical Care and Pulmonary Medicine

Specialty	Total
Family/Internal/General	806
Surgery	372
Otolaryngology	421
Allergy	157
Pediatrics	48
Emergency	42
Dermatology	28
Anesthesiology	29
Cardiology	28
Radiology	22
Critical Care/Hospital	23
Pulmonary	10
Other	476
Total	2462

Level 2 Outcomes: Satisfaction

Analysis of participants' responses related to educational needs How well did the activity:




Learners
reported high
levels of
satisfaction
related to the
ability of the
activity to
impact practical
applications



Level 3 Outcomes: Overall Knowledge

80% Relative Knowledge Gain

37% Absolute Knowledge Gain






Level 3&4 Outcomes: Knowledge & Competence (Q1)

Learning Objective: Explain the characteristics of nasal polyps and key concepts relative to the pathophysiology and immunology of CRSwNP.

Question 1: Which of the following cytokines are characteristic of the type 2 inflammation seen in the majority of patients with chronic rhinosinusitis with nasal polyps in the United States?






Level 3&4 Outcomes: Knowledge & Competence (Q2)

Learning Objective: Describe best practices for diagnosis and comprehensive assessment of CRSwNP.


Question 2: The ideal time to obtain CT imaging in the work-up of CRSwNP is:



Level 3&4 Outcomes: Knowledge & Competence (Q3)

Learning Objective: Analyze strategies for longitudinal management of CRSwNP.


Question 3: The duration of quality of life improvement following surgery for CRSwNP has been shown to be clinically significant for up to:



Level 3&4 Outcomes: Knowledge & Competence (Q4)

Learning Objective: Select treatments based on individual patient factors and recent clinical studies regarding current and emerging treatment options for CRSwNP.

Question 4: A 54-year old female with history of chronic idiopathic urticaria, moderate persistent atopic asthma, and chronic rhinosinusitis with nasal polyposis presents for follow up. She had sinus surgery 3 years ago with improvement in sinus symptoms, but progressive worsening over the past year. She is adherent to her steroid nasal irrigations twice daily, and co-morbidities have been addressed. Her eosinophil count is 300, and total IgE level is 300. Assuming that all of these biologics get approved by the FDA, which of the following would be most beneficial for this particular patient?



Level 4 Outcomes: Competence

An analysis of open-ended comments demonstrates the following changes learners intend to make:

89%

N=2070

Evaluation respondents intend to make changes to practice as a result of the activity

Use biologic therapy when appropriate [N=181]

Apply new knowledge of CRSwNP to improve patient care and education [N=113]

Improve diagnostic workup [N=102]

Apply guidelines to improve longitudinal management of CRSwNP

[N=84]

Refer to a specialist when needed

[N=39]

Program Evaluation Results

Diagnostic workup (54 responses)

Treatment Options

(121 responses)

Overall longitudinal management (123 responses)

Most

important

take-away

Increased

Knowledge of

CRSwNP pathophysiology and outcomes

(180 responses)

Management of biologics and other therapies

(154 responses)

98%

 Material presented in an objective manner and free of commercial bias

97%

 Content presented was evidencebased and clinically relevant

N = 2069



Program Evaluation Results

Barriers Encountered in Practice:

- Access to care and cost
- Access to equipment
- Access to treatment or clinical trials
- Conflicting evidence
- Cost of therapy
- Lack of training
- Medication use/biologic therapies
- Patient adherence
- Patient knowledge
- Staffing

60%

N=621

Evaluation
respondents
indicated the activity
addressed strategies
for overcoming
barriers to optimal
patient care



Program Evaluation Results

What topics would you like more information about in future educational activities?			
Allergic Rhinitis	Current guidelines on common ENT cases		
Asthma	Immunotherapy for nasal polyps		
Biologic agents and usage	Surgical and non-surgical options for nasal polyps		
Chronic pain management	New therapeutic agents		
Chronic refractory cough	Infectious acute sinusitis		
Chronic rhinitis without nasal polyps	Idiopathic angioedema		
Communicable disease	Hypoparathyroidism		
COVID-19	Polyposis		
Corticosteroids	Evaluation of allergy		
Fungal rhinosinusitis	Sinusitis		
Eczema	Urticaria management		



Accreditation

NJH is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The NJH Office of Professional Education produced and accredited this program and adhered to the updated ACCME guidelines.

NJH designates this enduring material for a maximum of 1.0 *AMA PRA Category 1 Credit*™.



